logo-loader
Kazia Therapeutics Ltd

Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women.

Kazia Therapeutics Ltd - Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study
Initial data from Part B is expected in the fourth quarter of calendar 2019

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has completed the recruitment of patients into Part B of its phase I clinical study of Cantrixil in ovarian cancer.

Cantrixil is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.

Background

Part A of the study collected data from an initial 14 patients, who received escalating doses of Cantrixil to determine safety and tolerability.

A maximum tolerated dose of 5 mg/kg was achieved, and this data was reported at the American Association of Cancer Research conference on April 1 2019.

Final completion of the study in 2020

Part B was designed to enroll 12 patients, all of whom will receive Cantrixil at a dose of 5 mg/kg. Part B will seek preliminary signals of potential efficacy for the drug.

Initial data from Part B is expected in the fourth quarter of calendar 2019, with final completion of the study in 2020.

Kazia chief executive officer Dr James Garner said: “Part B of the Cantrixil study has recruited well and we are now following patients through to completion of their treatment.

“We are grateful for the excellent efforts of the participating clinicians, and of the study team. The first part of the study has shown some very promising signals, and the data from Part B will significantly enhance our understanding of the drug.

“We will be presenting data at the ESMO conference at the end of September, and this will be valuable opportunity to move forward our partnering discussions for Cantrixil.”

Low survival rate for ovarian cancer

About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women.

Conventional treatment typically includes surgery, radiotherapy, and chemotherapy.

However, the five-year survival rate remains low, at about 45%, reflecting the fact that the disease is often advanced at the time of diagnosis.

Quick facts: Kazia Therapeutics Ltd

Price: $0.37

Market: ASX
Market Cap: $23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment.    Garner said the superior results from the ongoing study of...

on 7/5/19

2 min read